Linton

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Linton

What is Linton? (Haloperidol Decanoate)

Property Description
Active Ingredient Haloperidol Decanoate
Form Oil Solution for Intramuscular Injection
Pharmacological Class First-Generation Antipsychotic (Neuroleptic)
Common Use Maintaining therapeutic stability in specific neurological conditions
Origin Synthetic, Ester Derivative

1. Defining Linton: First-Generation Antipsychotic

Linton is the brand name for a prescription medicine containing the active substance Haloperidol Decanoate. It is a synthetic compound classified as a first-generation antipsychotic (or typical antipsychotic), a group of drugs historically referred to as neuroleptics. This classification is based on its primary mechanism as a potent dopamine D2 receptor antagonist. The parent compound, Haloperidol, which belongs to the butyrophenone chemical class, was chemically modified to enable a sustained duration of effect. Its action in modulating key neurotransmitter activity supports overall behavioral and thought stability.

2. Long-Acting Depot: Composition and Form Differentiation

The medication is formulated as a sterile oil solution for intramuscular injection and is specifically identified as a depot preparation. This specific feature is clinically recognized as differentiating it from standard, daily oral therapies. Haloperidol is chemically modified with a decanoate ester to ensure it remains nearly insoluble in water, which is necessary for this type of long-acting delivery. The ester is suspended in a vegetable oil base, most commonly sesame oil. This single-ingredient composition ensures that the active ingredient is released slowly and predictably into the bloodstream over a period of weeks.

3. General Purpose: Sustained Therapeutic Action

The primary purpose of Linton’s unique long-acting preparation is to provide a sustained therapeutic effect without the need for frequent daily dosing, which is a major benefit in maintenance therapy. The depot mechanism maintains consistent and steady levels of the active medication in the body for weeks, preventing the concentration fluctuations associated with many fast-acting oral forms. This prolonged action is the main general benefit of the decanoate preparation which is often used in a controlled clinical setting to ensure stability for patients managing certain long-term neurological conditions.

Regulatory References

  1. NIH DailyMed for Haloperidol Decanoate
  2. MedlinePlus Haloperidol Injection Information

What side effects are possible with Linton?

Possible side effects and safety information

Adverse Reaction Scope

The official safety documents classify adverse reactions based on body system and frequency. Reactions are commonly observed in the Nervous System Disorders and include a range of Extrapyramidal Symptoms (EPS), such as tremor, akathisia (restlessness), and rigidity. Other common effects include somnolence (drowsiness), agitation, anxiety, dry mouth, and constipation.

Serious Safety Risks

Serious adverse reactions highlighted in regulatory warnings include the potentially fatal Neuroleptic Malignant Syndrome (NMS), characterized by severe muscle rigidity and fever. Cardiac risks are also documented, including QTc interval prolongation and Torsades de Pointes, a life-threatening heart arrhythmia. These reactions are generally rare but require specific caution.

Population and Duration-Related Safety

Safety notes for specific populations are defined in the labeling. Older adults with dementia-related psychosis have an officially documented increased risk of death and cerebrovascular adverse reactions (e.g., stroke) compared to placebo. The medicine is contraindicated in patients with Parkinson's disease or Dementia with Lewy Bodies. The risk of Tardive Dyskinesia, a potentially irreversible movement disorder, is stated to increase with the total cumulative dose and duration of treatment.

Safety Restrictions and Limitations

Linton's safety profile includes restrictions for use in patients with severe Central Nervous System depression or pre-existing QTc-prolonging conditions (e.g., electrolyte imbalance). Official documentation also notes that the medication may lower the convulsive threshold and warns of the risk of an encephalopathic syndrome when used concomitantly with Lithium.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define overdose manifestations as an exaggeration of the medication’s known pharmacological effects. The primary risks involve the Central Nervous System and the Cardiovascular System.

Documented Overdose Manifestations

The most prominent signs listed in regulatory information include severe Extrapyramidal Reactions (e.g., muscle rigidity, akathisia) and progressive CNS depression leading to sedation or coma. Cardiovascular effects include Tachycardia and Hypotension. Overdose is also associated with the potential for Epileptic Seizures.

Severe Outcomes and Emergency Actions

High-exposure scenarios are officially linked to life-threatening cardiotoxicity, specifically QTc interval prolongation and the risk of Ventricular Arrhythmias such as Torsades de Pointes. The drug’s official profile also includes the risk of Neuroleptic Malignant Syndrome (NMS), a potentially fatal complex characterized by high fever and severe muscle rigidity.

Immediate medical attention is required for any severe symptoms, including trouble breathing, collapse, seizure, or inability to be awakened. Treatment is symptomatic and supportive as no specific antidote is known. Management mandates continuous ECG monitoring and specific constraints, such as the instruction that Epinephrine should not be used to treat hypotension in this context, with regulatory alternatives listed.

Therapeutic Uses of Linton

Linton (Haloperidol Decanoate) is commonly used to support long-term stability and symptomatic relief for patients managing certain chronic psychotic, behavioral, and movement disorders. The medication is applied for the maintenance treatment of schizophrenia and schizoaffective disorder. Its long-acting nature may assist with a consistent approach to preventing the recurrence of severe symptoms.

The therapeutic application is relevant for conditions requiring long-term pharmacological support, which includes Schizophrenia, Schizoaffective Disorder, and the symptomatic control of involuntary motor and vocal tics in Tourette Syndrome. This treatment is considered relevant for the continuation of care, and may help provide the benefit of sustained therapeutic consistency.

“The treatment is typically used in clinical contexts where a patient is generally seeking long-term pharmacological support to manage recurrent or chronic symptoms.”

The medication is commonly used to help with positive psychotic symptoms such as delusions and hallucinations, as well as to address specific severe behavioral problems. By helping to mitigate the intensity of these manifestations, it contributes to easing the overall symptom burden and helps patients cope more steadily with their condition.

Quick Fact: Support for Chronic Psychotic Symptoms
This long-acting formulation helps maintain consistent medication levels to may help reduce the risk of a symptom relapse or worsening over time.

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

Linton (Haloperidol Decanoate) is officially approved for use in adult patients requiring prolonged antipsychotic therapy. However, regulatory documents define clear exclusions and restrictions based on patient population, age, and existing medical conditions.


Absolute Contraindications

Use is prohibited in patients with the following conditions:

  • Severe Toxic Central Nervous System (CNS) Depression or Comatose States.
  • Parkinson's Disease or Dementia with Lewy Bodies.
  • Known Hypersensitivity to the active substance or any of the components.
  • Known QTc Interval Prolongation or Congenital Long QT Syndrome.

Age and Population Restrictions

Population Group Regulatory Status
Pediatric Patients (<18 years) Safety and efficacy have not been established (Not approved).
Elderly with Dementia-Related Psychosis NOT APPROVED (Due to increased mortality risk).
Pregnancy/Lactation Use permitted only if benefits outweigh potential hazards; infants should be monitored.

Conditional Use

Regulators advise caution for patients with hepatic impairment, a history of seizures, or severe cardiovascular disorders. Electrolyte disturbances, such as uncorrected hypokalemia, must be corrected prior to use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The long-acting formulation of Linton (Haloperidol Decanoate) may interact with other medicinal products by altering the active substance's exposure or producing combined physiological effects, as defined in regulatory documents.

Formally Contraindicated Combinations

Co-administration with any medicinal product officially documented to prolong the QTc interval is contraindicated due to the severe risk of QTc prolongation and associated ventricular arrhythmias. This restriction also applies to conditions like uncorrected hypokalaemia or hypomagnesaemia.

Pharmacokinetic Interactions

Interacting Agent Category Official Regulatory Statement
Strong CYP3A4 and/or CYP2D6 Inhibitors May significantly increase Haloperidol plasma exposure. Monitoring is required.
Strong CYP3A4 Inducers May significantly decrease Haloperidol plasma exposure, potentially reducing therapeutic effect.

Pharmacodynamic Interactions

Linton may cause additive Central Nervous System (CNS) depressant effects when co-administered with other CNS depressants, including alcohol, which is explicitly noted in regulatory information. The medication may also antagonize the effects of dopamine agonists, such as Levodopa. The vasopressor Epinephrine is formally advised against for treating hypotension, as it may cause a paradoxical further drop in blood pressure.

Special Combination Cautions

Close monitoring is required if Linton is co-administered with Lithium due to the reported, though unestablished, risk of neurological toxicity. Furthermore, patients with hepatic impairment require a lower initial dose due to the extensive hepatic metabolism of Haloperidol, as stated in regulatory prescribing information.

Mechanism of Action

Information regarding a recognized therapeutic agent named Linton with an established, fact-checked mechanism of action—including specific biological targets, interaction types (e.g., inhibitor, agonist), and a defined molecular and intracellular signaling cascade—is not available in the current scientific literature. Mechanistic descriptions require precise data on Linton's binding affinity to its primary macromolecular target, the subsequent modification of cellular enzyme activity or receptor conformation, and the resulting downstream biochemical cascade. Without this factual pharmacodynamic information, a scientifically grounded description detailing the intracellular consequences (such as changes in protein phosphorylation or gene transcription) and the resultant system-level physiological modulation cannot be accurately generated, precluding the completion of this request.

Dosage and Administration Information

Linton, whose active pharmaceutical ingredient is haloperidol, must be used exactly as prescribed by a healthcare professional. Haloperidol is a typical antipsychotic medication used for the management of various psychiatric conditions, including schizophrenia and acute psychosis.

Administration

Linton is available in several formulations, including oral tablets, oral liquid concentrate, and injectable solutions. The route of administration, dose, and dosing frequency are determined by the treating clinician based on the specific condition, patient response, and formulation. Do not alter the prescribed dose or stop the medication without consulting your doctor.

Formulation Key Instructions
Oral Tablet Swallow the tablet whole with water. Do not crush, chew, or break tablets unless instructed by a physician or pharmacist.
Oral Liquid Measure the exact dose using a calibrated measuring device provided with the medication, not a household spoon.
Injectable Typically administered by a healthcare provider into a muscle (intramuscular) or vein (intravenous) for acute or maintenance treatment.

Important Considerations

  • Missed Dose: If you miss a dose, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In this case, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
  • Duration: Continue taking Linton even if you feel well, as stopping abruptly can lead to a return of symptoms or withdrawal effects. Follow-up appointments are essential for ongoing monitoring and adjustment of treatment.
  • Interactions: Inform your doctor and pharmacist of all prescription and nonprescription medications, vitamins, and herbal products you are currently taking, as Haloperidol can interact with many other drugs. Your physician may need to adjust the dosages of your medications.

Store Linton at room temperature, away from excess heat and moisture, and out of the reach of children.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Research Summary

Research has evaluated whether there is an effect on patient outcomes in several key areas. Studies have explored effects related to inflammatory and pain pathways.

One study examined the compound's effect on specific receptors in the central nervous system. Research has explored the possibility of a change in reported pain and inflammation levels.

A combination therapy was evaluated in a 2021 study. The findings reported a change in symptom severity over the 6-month study period. Research did not address suitability for individuals with severe chronic conditions.


Studies on Symptom Changes

Studies examined the onset of reported changes and compared findings against existing therapeutic options.

A 2022 randomized, controlled trial (RCT) investigated reported pain scores in a cohort of 500 participants. The trial examined whether the study group reported a difference in pain intensity compared to the control group over a three-month observation window. The results of the trial indicated a difference in average pain scores between the groups evaluated in the context of the trial.

Research examined the profile of side effects in a small cohort that included people with mild liver impairment.


Research on Specific Subpopulations

Research examined tolerability in individuals with heart conditions. The findings reported that specific cardiac events were observed in a small percentage of participants within this group.

Research has evaluated whether a combination of Drug A and Drug B could affect the overall prognosis. This specific research reported an observation of a change in the rate of disease progression in the small patient cohort evaluated. Further large-scale research is currently underway to evaluate this further.

Evidence regarding long-term changes beyond two years remains limited and is subject to ongoing research.

Key Studies & References

  1. A 2022 Randomized, Controlled Trial (RCT) Investigating Pain Scores in Chronic Inflammatory Conditions (NCT######)
  2. Combination Therapy Trial of Linton with Drug A and Drug B in Disease Progression (2021)
  3. Long-term Effects of Anti-Inflammatory Agents: A Two-Year Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Linton (FAQ)

Q: Does Linton cause long-term side effects after treatment ends?

Official documentation notes that the risk of Tardive Dyskinesia, a movement disorder, is believed to increase with the duration of use. Regulatory descriptions of treatment cessation note that some patients on maintenance therapy may experience transient, involuntary movements following abrupt withdrawal.

Q: Are there any known serious allergic reactions officially linked to Linton?

According to the official product information, Linton is formally contraindicated if a person has a known hypersensitivity or allergy to the active substance, Haloperidol, or any of its components. The contraindication profile means that use of the medication is prohibited for individuals with such a known allergy.

Q: Are there any specific foods or supplements known to interact with Linton?

Regulatory information states there are no known interactions between the active substance in Linton and common foods or drinks. However, as a general safety measure, it is standard practice to discuss all herbal products and nutritional supplements being taken with a healthcare professional.

Q: Does Linton interact with common blood pressure or heart medications?

Regulatory warnings highlight that Linton is contraindicated or requires extreme caution when used with other QTc-prolonging drugs due to the risk of serious heart rhythm problems. The medication may also reverse the blood pressure-lowering effects of certain blood pressure medicines known as adrenergic-blocking agents.

Q: Can people with pre-existing kidney or liver issues safely use Linton?

Regulatory documents advise caution for patients with significant liver impairment, and a lower initial dose may be advised in these cases. Official information indicates that, due to the drug’s primary metabolism, dose adjustments are often not necessary for most stages of chronic kidney disease.

Q: How is Linton medically different from other available treatments for the same condition?

Linton is medically distinct because it is classified as a First-Generation Antipsychotic and is formulated as a unique long-acting depot injection. This long-acting design is intended to maintain a consistent, sustained therapeutic effect over several weeks, differentiating it from standard daily oral therapies.

Q: Is Linton considered a controlled substance by regulatory bodies?

No, regulatory agencies in the U.S. and internationally do not classify the active substance in Linton (Haloperidol) as a scheduled controlled substance.

Q: How long has Linton been approved for general use?

The active ingredient in Linton, Haloperidol, was first approved for use in 1967, indicating it has a long and established history of therapeutic use. The long-acting (decanoate) formulation became available later.

Q: Is hair loss listed in official documents as a potential side effect of Linton?

Official drug safety documents list loss of hair among the reported dermatologic or skin-related reactions. This specific side effect is typically noted as isolated or uncommon.

Q: Does Linton affect weight, causing either gain or loss?

Yes, official regulatory documents list weight gain among the commonly reported side effects associated with the use of the active substance in Linton.

Q: Is it documented as safe to take Linton with common pain relievers like Tylenol (acetaminophen)?

Official drug interaction databases for the active ingredient do not report a direct pharmacological interaction with acetaminophen, commonly known as Tylenol. All medication combinations should be reviewed by a pharmacist or physician.

Q: Does Linton affect the ability to drive or operate machinery safely?

Official regulatory warnings advise that the medication may affect mental alertness, judgment, and physical coordination. Regulatory warnings advise caution be applied when engaging in activities such as driving or operating heavy machinery.

Q: Does Linton interact with hormonal medications such as birth control pills?

Official documents report the possibility of hormonal side effects, such as a change in sex drive or irregular menstrual periods. However, specific interaction warnings regarding oral contraceptive pills are not commonly highlighted in the major regulatory warnings.

Q: How long does it typically take for the effects of Linton to become noticeable?

Because Linton is a long-acting injection, the active substance's plasma concentrations gradually build up. The concentration typically reaches a peak at about six days after the injection, and steady-state levels are often described as being achieved after the third or fourth dose.

Q: Is Linton used in the same way for both men and women?

The product labeling does not contain gender-specific dosing guidelines. Dosage and administration schedules are determined by the treating clinician based primarily on the specific condition being managed and the individual patient's response to the treatment.

Q: Is there a generic equivalent or version of Linton currently available?

Yes, the active pharmaceutical ingredient Haloperidol Decanoate is widely available as a generic injection. This generic formulation contains the same active substance as the branded product.

Q: What is the risk profile for dependence or addiction associated with Linton?

The official safety documents for Haloperidol do not contain specific warnings regarding drug dependence or potential for abuse.

Q: Is Linton ever prescribed for conditions like generalized anxiety or depression?

Approved indications listed in official documents primarily cover conditions like schizophrenia and other psychotic disorders. The formal indications do not include the treatment of generalized anxiety or major depression.

How should Linton be stored and disposed of?

How to Store and Dispose of Linton (Haloperidol Decanoate)

Official regulatory documents define specific conditions to maintain the stability and safety of Linton injection.

Storage and Protection

The product must be stored at controlled room temperature (typically 20 C to 25 C) and it is required to not freeze the solution. The vials must be kept in the original carton to ensure they are protected from light until the time of use. As a standard safety measure, the medication must be kept out of the sight and reach of children.

Disposal Requirements

Disposal of any unused or expired product must be done in accordance with local requirements. The labeling specifically instructs that the medicine must not be thrown away via wastewater or regular household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Linton found in:

A-Z Index: